These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Flombaum CD; Mouradian JA; Casper ES; Erlandson RA; Benedetti F Am J Kidney Dis; 1999 Mar; 33(3):555-62. PubMed ID: 10070921 [TBL] [Abstract][Full Text] [Related]
30. A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. Kozuch P; Petryk M; Bruckner HW Hematol Oncol Clin North Am; 2002 Feb; 16(1):123-38. PubMed ID: 12063823 [TBL] [Abstract][Full Text] [Related]
32. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. Gross M; Hiesse C; Kriaa F; Goldwasser F Anticancer Drugs; 1999 Jul; 10(6):533-6. PubMed ID: 10885900 [TBL] [Abstract][Full Text] [Related]
33. Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report. Citarrella P; Gebbia V; Teresi M; Miceli S; Sciortino G; Vaglica M; Pizzardi N; Palmeri S Anticancer Res; 2002; 22(2B):1183-5. PubMed ID: 12168922 [TBL] [Abstract][Full Text] [Related]
34. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Bharthuar A; Egloff L; Becker J; George M; Lohr JW; Deeb G; Iyer RV Cancer Chemother Pharmacol; 2009 Jun; 64(1):177-81. PubMed ID: 19116715 [TBL] [Abstract][Full Text] [Related]
36. Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review. Ritchie GE; Fernando M; Goldstein D Cancer Chemother Pharmacol; 2017 Jan; 79(1):1-7. PubMed ID: 27497971 [TBL] [Abstract][Full Text] [Related]
37. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15. Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407 [TBL] [Abstract][Full Text] [Related]
38. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? Gore EM; Jones BS; Marques MB J Clin Apher; 2009; 24(5):209-14. PubMed ID: 19816959 [TBL] [Abstract][Full Text] [Related]
39. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Rabinowits G; Herchenhorn D; Rabinowits M; Weatge D; Torres W Anticancer Drugs; 2003 Sep; 14(8):665-8. PubMed ID: 14501391 [TBL] [Abstract][Full Text] [Related]
40. [Hemolytic-uremic syndrome complicating a long-term treatment with gemcitabine. Report of a case and review of the literature]. Dilhuydy MS; Delclaux C; Pariente A; De Precigout V; Aparicio M Rev Med Interne; 2002 Feb; 23(2):189-92. PubMed ID: 11876063 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]